42
  • Monoclonal Anti-Ubiquitinated histone H2B antibody (No. 1397)

    Scientist: Moshe Oren

    A novel antibody which can be used, for the first time, to recognize ubiquitinated histone 2B. This technology is novel in its ability to recognize proteins and their destinations, and may serve in diagnostics and immunoprecipitation processes. ... Read more
    5464
  • P38 and JNK inhibitor as potential treatment for various pathologies (No. 1733)

    Scientist: Rony Seger

    Recently, Prof. Zeger and his team discovered a new level of regulation to stimulated transcription. They showed that ?-like importunes are central mediators of nuclear translocation of signaling proteins. Furthermore they identified the site of interaction and designed accordingly a peptide which was found to prevent nu ... Read more
    5605
  • A Method in Improving Survival and Expansion of Hematopoietic Stem Cells (No. 1874)

    Scientist: Idit Shachar

    hematopoietic cells. HSCs have the capacity to both self-renew and to differentiate, and they migrate from the bone marrow to the blood upon demand. Since HSCs can differentiate to a variety of cell types, including immune system cells, they have a huge therapeutic potential. Indeed, bone marrow transplantation is a comm ... Read more
    5716
  • CD84 - a Novel Regulator of B-CLL Survival (No. 1441)

    Scientist: Idit Shachar

    Chronic lymphocytic leukemia (CLL), a malignant disease characterized by the accumulation of B lymphocytes in the blood, lymphoid organs, and bone marrow, is the second most common type of leukemia in adults, accounting for about 7,000 new cases of leukemia each year. Presently, there is no cure for CLL, and the overall ... Read more
    5470
  • CO2 Fixation with Bioengineered Microorganisms (No. 1736)

    Scientist: Ron Milo

    Biomass production by plants and other photosynthetic organisms involves carbon fixation, the process of incorporating inorganic carbon dioxide into organic compounds. Currently carbon fixation by plants and other photosynthetic organisms is the limiting factor in biomass production. Improvement in the metabolic pathway ... Read more
    5608
  • Inhibiting Importin to Treat Psychiatric Stress and Other Disorders (No. 1875)

    Scientist: Michael Fainzilber

    Anxiety and stress-related disorders effect 10-30% of the general population and are therefore considered a major burden on public health. Current medical treatments for anxiety disorders include drugs that target various synaptic mechanisms, such as uptake of neurotransmitters. However, severe side-effects and suboptima ... Read more
    5719
  • Inhibition of Nuclear Entry of MAPK Cascade Proteins as a Novel Mechanism for Treating Cancer (No. 1446)

    Scientist: Rony Seger

    Peptide sequences for efficient inhibition of nuclear translocation of proteins. The ability to regulate cellular localization of a biological component is important for many functions such as gene therapy, protection from toxic chemicals, transport of anti-cancer agents, and possibly preventing nuclear translocation of ... Read more
    5473
  • A Novel Approach for Treating Cancer and Collagen-Associated Diseases by Using Anti-LOXL-2 Antibody (No. 1743)

    Scientist: Irit Sagi

    Disruption to the Extra-Cellular Matrix (ECM) is associated with many pathological conditions, such as various cancer types and tissue fibrosis, and also correlates with high tumor malignancy. Therefore, controlling ECM composition and morphology is considered a potential treatment for cancer and other ECM-associated dis ... Read more
    5611
  • Universal CAR-Ts (No. 1884)

    Scientist: Zelig Eshhar

    Chimeric Antigen Receptor T-Cells (CAR-Ts) are one of the revolutionary technologies of the twenty-first century, invented by Prof. Zelig Eshhar at the Weizmann Institute of Science. The CAR-T technology represents a leap in terms of treating cancer, as the technology programs an individual’s immune system to specifica ... Read more
    5722
  • MicroRNA Differental Profiles as ALS Biomarkers (No. 1498)

    Scientist: Eran Hornstein

    MicroRNAs as potential biomarkers for ALS.Amyotrophic Lateral Sclerosis (ALS) is a devastating disease that progressively destroys motor neurons in the brain and the spinal cord, eventually causing paralysis and death. Currently, there are approximately 25,000 patients with ALS in the USA, with a median age of onset of ... Read more
    5488

Pages

Subscribe to Pharmaceuticals